1
|
Christensen D, Ghafoor M, Goldberg A, De Cotiis DA, Chan JSY. Tumor Budding, Poorly Differentiated Clusters, and Stroma Percentage in Uterine Endometrioid Carcinomas Are Morphologic Findings Associated With Adverse Clinical Outcomes. Int J Gynecol Pathol 2025; 44:49-55. [PMID: 39661577 DOI: 10.1097/pgp.0000000000001028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2024]
Abstract
Uterine endometrioid carcinoma (UEC) has well-defined morphologic features that carry prognostic significance and guide treatment. In addition to the well-known features, tumor budding (TB), poorly differentiated clusters (PDCs), and amount of stroma within the invasive front are associated with a poor prognostic outcome in many carcinomas. Here, we evaluate TB, PDCs, and the stroma percentage in UEC and correlate these findings with morphologic features known to be associated with a poor clinical outcome and with recurrence-free survival (RFS). We performed a retrospective search of our institution's EMR for cases of hysterectomy for UEC. We collected clinical data including disease recurrence, death, and data associated with poor patient outcomes. Cases were evaluated for TB, PDCs, and percent stroma by 2 pathologists. Ten 20× fields were examined, and the one with the most PDCs and TB was evaluated. Percent stroma was evaluated in a ×10 field of tumor at the area of deepest invasion. Less than 10% stroma was defined as stroma poor, and >10% stroma was defined as stroma rich. Statistical testing and analysis were conducted, and P-value was set at 0.05. One hundred thirteen cases were evaluated. Decreased RFS was seen with TB (P=0.03), at least 5 PDCs (P=0.01), and stroma-rich tumors (P=0.043). This study shows a statistically significant association between TB presence, at least 5 PDCs, stroma-rich tumors, and decreased RFS in UEC. We conclude that TB, PDCs and stromal evaluation are strong independent prognostic indicators in UEC and provide additional value to the currently used morphologic assessment of UEC.
Collapse
|
2
|
Cacchi C, Fischer HJ, Wermker K, Rashad A, Jonigk DD, Hölzle F, Klein M. New Tumor Budding Evaluation in Head and Neck Squamous Cell Carcinomas. Cancers (Basel) 2024; 16:587. [PMID: 38339338 PMCID: PMC10854693 DOI: 10.3390/cancers16030587] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2023] [Revised: 01/25/2024] [Accepted: 01/27/2024] [Indexed: 02/12/2024] Open
Abstract
BACKGROUND Tumor budding (TB) is a histomorphological characteristic of the tumor invasion front and it has an impact on the tumor outcome prediction for head and neck squamous cell carcinoma (HNSCC) aetiopathology. PATIENTS AND METHODS The average TB score (TB rel) of all tumor-positive marginal sections (n = 443) in the primary tumor was analyzed in the FFPE-fixed tumor slices of 66 patients with HNSCC, and they were compared with cryo-fixed sections. RESULTS TB rel correlates with tumor aggressiveness (i.e., lymph node metastasis quantity, lymph node ratio, extra capsular growth, Pn1, pV1, grading). The TB scores often vary between the different tumor margins of FFPE sections in the same patient, and in many cases, they differ depending on the fixation method. CONCLUSION Our data show that a randomly selected marginal cut cannot reliably mirror the TB score, and thus, they cannot predict the prognostic outcome. However, TB rel could be a tool that compensates for differences in TB score analysis. TB score determination in cryo sections seems to be inaccurate compared with TB determination in FFPE.
Collapse
Affiliation(s)
- Claudio Cacchi
- Institute of Pathology, School of Medicine, University Hospital RWTH Aachen, Pauwelsstrasse 30, 52074 Aachen, Germany; (C.C.); (D.D.J.)
| | - Henrike J. Fischer
- Institute of Immunology, School of Medicine, University Hospital RWTH Aachen, Pauwelsstrasse 30, 52074 Aachen, Germany;
| | - Kai Wermker
- Department of Oral and Cranio-Maxillofacial Surgery, Klinikum Osnabrück GmbH, Am Finkenhügel 1, 49076 Osnabrück, Germany;
| | - Ashkan Rashad
- Department of Oral and Maxillofacial Surgery, School of Medicine, University Hospital RWTH Aachen, Pauwelsstrasse 30, 52074 Aachen, Germany; (A.R.); (F.H.)
| | - Danny D. Jonigk
- Institute of Pathology, School of Medicine, University Hospital RWTH Aachen, Pauwelsstrasse 30, 52074 Aachen, Germany; (C.C.); (D.D.J.)
- German Center for Lung Research (DZL), Breath Hanover, 30625 Hanover, Germany
| | - Frank Hölzle
- Department of Oral and Maxillofacial Surgery, School of Medicine, University Hospital RWTH Aachen, Pauwelsstrasse 30, 52074 Aachen, Germany; (A.R.); (F.H.)
| | - Maurice Klein
- Department of Oral and Maxillofacial Surgery, School of Medicine, University Hospital RWTH Aachen, Pauwelsstrasse 30, 52074 Aachen, Germany; (A.R.); (F.H.)
| |
Collapse
|
3
|
Stögbauer F, Geß B, Brambs C, Lautizi M, Kacprowski T, Ourailidis I, Bronger H, Kiechle M, Noske A, Keller G, Jesinghaus M, Poremba C, Weichert W, Boxberg M. Independent Tissue-Based Biomarkers in Endometrioid Endometrial Cancer: Tumor Budding in Microsatellite Instability and WHO Grading in Copy-Number-Low Patients. Cancers (Basel) 2023; 15:3832. [PMID: 37568650 PMCID: PMC10416921 DOI: 10.3390/cancers15153832] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2023] [Revised: 07/20/2023] [Accepted: 07/21/2023] [Indexed: 08/13/2023] Open
Abstract
The molecular characterization of endometrial endometrioid adenocarcinomas has provided major advances in its prognostic stratification. However, risk assessment of microsatellite instability (MSI) and copy-number (CN)-low cases remains a challenge. Thus, we aimed to identify tissue-based morphologic biomarkers that might help in the prognostic stratification of these cases. Histomorphologic parameters (WHO grading, tumor budding (TB), tumor-stroma ratio (as a quantitative description of stromal desmoplasia), tumor-infiltrating lymphocytes (TIL), "microcystic, elongated, fragmented" (MELF) pattern) were analyzed in resection specimens of the TCGA-UCEC cohort (n = 228). For each quantitative parameter, a two-tiered system was developed utilizing systematically determined cutoffs. Associations with survival outcomes were calculated in univariate and multivariate analysis and validated in two independent cohorts. In MSI tumors, only TB remained an independent prognostic factor. TB (≥3 buds/high-power field) was associated with inferior outcomes and with lymph node metastases. The prognostic significance of TB was confirmed in two validation cohorts. For CN-low tumors, established grading defined by the WHO was independently prognostic with inferior outcomes for high-grade tumors. The evaluation of TB might help in identifying MSI-patients with unfavorable prognosis who, e.g., could benefit from lymphadenectomy. WHO-based grading facilitates independent prognostic stratification of CN-low endometrioid adenocarcinomas. Therefore, we propose the utilization of TB and WHO-based grading, two tissue-based and easy-to-assess biomarkers, in MSI/CN-low endometrial carcinomas for improved clinical management.
Collapse
Affiliation(s)
- Fabian Stögbauer
- Institute of Pathology, School of Medicine, Technical University of Munich (TUM), 81675 Munich, Germany; (F.S.); (M.L.); (A.N.); (G.K.); (W.W.)
| | - Barbara Geß
- Department of Obstetrics and Gynecology, Technical University of Munich, 81675 Munich, Germany; (B.G.); (H.B.)
| | - Christine Brambs
- Lucerne Cantonal Hospital, Department of Obstetrics & Gynecology, Division of Gynecologic Oncology, 6000 Lucerne, Switzerland;
| | - Manuela Lautizi
- Institute of Pathology, School of Medicine, Technical University of Munich (TUM), 81675 Munich, Germany; (F.S.); (M.L.); (A.N.); (G.K.); (W.W.)
- Chair of Experimental Bioinformatics, TUM School of Life Sciences Weihenstephan, Technical University of Munich, 85354 Freising, Germany
| | - Tim Kacprowski
- Division Data Science in Biomedicine, Peter L. Reichertz Institute for Medical Informatics, TU Braunschweig and Hannover Medical School, 38106 Brunswick, Germany;
- Braunschweig Integrated Centre of Systems Biology (BRICS), 38106 Brunswick, Germany
| | - Iordanis Ourailidis
- Institute of Pathology, Heidelberg University Hospital, 69120 Heidelberg, Germany;
| | - Holger Bronger
- Department of Obstetrics and Gynecology, Technical University of Munich, 81675 Munich, Germany; (B.G.); (H.B.)
- German Cancer Consortium (DKTK) Partner Site Munich, 81675 Munich, Germany
| | - Marion Kiechle
- Department of Obstetrics and Gynecology, Technical University of Munich, 81675 Munich, Germany; (B.G.); (H.B.)
| | - Aurelia Noske
- Institute of Pathology, School of Medicine, Technical University of Munich (TUM), 81675 Munich, Germany; (F.S.); (M.L.); (A.N.); (G.K.); (W.W.)
| | - Gisela Keller
- Institute of Pathology, School of Medicine, Technical University of Munich (TUM), 81675 Munich, Germany; (F.S.); (M.L.); (A.N.); (G.K.); (W.W.)
| | - Moritz Jesinghaus
- Institute of Pathology, University Hospital Marburg, Baldingerstraße, 35043 Marburg, Germany;
| | | | - Wilko Weichert
- Institute of Pathology, School of Medicine, Technical University of Munich (TUM), 81675 Munich, Germany; (F.S.); (M.L.); (A.N.); (G.K.); (W.W.)
- German Cancer Consortium (DKTK) Partner Site Munich, 81675 Munich, Germany
| | - Melanie Boxberg
- Institute of Pathology, School of Medicine, Technical University of Munich (TUM), 81675 Munich, Germany; (F.S.); (M.L.); (A.N.); (G.K.); (W.W.)
- German Cancer Consortium (DKTK) Partner Site Munich, 81675 Munich, Germany
- Pathologie München-Nord, 80992 Munich, Germany;
| |
Collapse
|